AN2 Therapeutics Q4 EPS $(0.57) Beats $(0.76) Estimate
Portfolio Pulse from Benzinga Newsdesk
AN2 Therapeutics (NASDAQ:ANTX) reported Q4 earnings with losses of $(0.57) per share, surpassing the analyst consensus estimate of $(0.76) by 25%. This represents a 6.56% improvement over the previous year's losses of $(0.61) per share.
March 28, 2024 | 8:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AN2 Therapeutics reported a smaller-than-expected loss per share in Q4, beating estimates and showing year-over-year improvement.
Beating earnings estimates typically leads to positive investor sentiment, potentially driving up the stock price in the short term. The improvement over the previous year's losses further strengthens the case for a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100